- Home
- PSNL vs ONCY Comparison
PSNL vs ONCY Comparison
Compare PSNL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ONCY |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 106.1M |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ONCY |
|---|---|---|
| Price | $8.97 | $1.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $10.71 | $6.00 |
| AVG Volume (30 Days) | ★ 1.6M | 695.5K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $0.33 |
| 52 Week High | $11.40 | $1.51 |
Technical Indicators
Market Signals| Indicator | PSNL | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 46.86 |
| Support Level | $9.34 | $0.94 |
| Resistance Level | $9.85 | $1.01 |
| Average True Range (ATR) | 0.70 | 0.06 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 2.17 | 69.83 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.